SOLIGENIX, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
SOLIGENIX, INC. (SNGX) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $2.88 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2021-03-30
- SOLIGENIX, INC. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2020 was $2.88.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|
| 2020-12-31 | $2.88 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |